Karyopharm Therapeutics
Julia Connolly, MBA, currently serves as a Senior Corporate Accountant at Karyopharm Therapeutics Inc., a position held since November 2022. Prior to this, Julia worked as a Staff Accountant at Sullivan and Folan, LLC from November 2019 to October 2022, and completed a Financial Planning Internship at Davis Wealth Advisors from September 2018 to May 2019. Julia earned a Bachelor of Arts in Finance from Saint Anselm College in 2019 and is currently pursuing a Master of Business Administration at the Questrom School of Business, Boston University, with an expected graduation in 2024.
Karyopharm Therapeutics
13 followers
Karyopharm Therapeutics Inc. (Nasdaq: KPTI) is an innovation-driven pharmaceutical company dedicated to the discovery, development, and commercialization of novel first-in-class drugs directed against nuclear export and related targets for the treatment of cancer and other major diseases. Karyopharm's Selective Inhibitor of Nuclear Export (SINE) compounds function by binding with and inhibiting the nuclear export protein XPO1 (or CRM1).